Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients - Abstract

PURPOSE: Comparative data related to the use of open and minimally invasive surgical approaches for the treatment of high-risk prostate cancer (PCa) remain limited.

We determined outcomes of open radical prostatectomy (RRP), laparoscopic RP (LRP), and robot-assisted RP (RARP) in matched cohorts of patients with high-risk prostate cancer.

MATERIALS AND METHODS: A total of 805 patients with high-risk PCa (prostate-specific antigen (PSA) >20 ng/mL, Gleason score ≥8, or clinical stage ≥cT2c) were identified. A total of 407 RRP cases were propensity score (PS) matched 1:1 to 398 LRP or RARP cases to yield 3 cohorts (RARP, LRP, and RRP) of 110 patients each for analysis. PS matching variables included the following: age, clinical stage, preoperative PSA, biopsy Gleason score, surgeon experience, and nerve-sparing technique. Overall survival (OS) and recurrence-free survival (RFS) were compared with log-rank test. RFS predictor analysis was calculated within Cox regression models.

RESULTS: Pathological Gleason scores < 7, =7, and >7 were found in 3.3, 50.9, and 45.8 % of patients. There were no statistically significant differences for pathological stage and positive surgical margins between surgical techniques. Mean 3-year RFS was 41.4, 77.9, and 54.1 %, for RARP, LRP, and RRP, respectively (p < 0.0001 for RARP vs. LRP). There were no significant differences for mean estimated 3-year OS for patients treated with RARP, LRP, or RRP (95.4, 98.1, and 100 %).

CONCLUSIONS: RARP demonstrated similar oncologic outcomes compared to RRP and LRP in a PS-matched cohort of patients with high-risk prostate cancer.

Written by:
Busch J, Magheli A, Leva N, Hinz S, Ferrari M, Friedersdorff F, Fuller TF, Miller K, Gonzalgo ML.   Are you the author?
Department of Urology, Charité University Medicine Berlin, Berlin, Germany.  

Reference: World J Urol. 2014 Mar 9. Epub ahead of print.
doi: 10.1007/s00345-014-1270-0


PubMed Abstract
PMID: 24609219

UroToday.com Prostate Cancer Section